Balaxi Pharmaceuticals Ltd
BALAXI
Company Profile
Business description
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
Contact
Phase-III, Road No: 81, Jubilee Hills
Plot No.409, H,No: 8-2-293
MAPS Towers, 3rd Floor
HyderabadTG500 096
INDT: +91 4023555300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
69
Stocks News & Analysis
stocks
SK Hynix Earnings: We raise fair value estimate on strong AI memory demand
Shares jumped 9% after earnings, as stronger AI memory prices boosted the chipmaker’s outlook.
stocks
Meta shares are down 12% since earnings. Is the stock a buy?
Concerns about equity sales to finance AI investments have pressured shares.
stocks
SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?
AI data center revenue is growing fast, but questions about durability remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,002.70 | 31.30 | 0.35% |
| CAC 40 | 7,886.96 | 0.18 | -0.00% |
| DAX 40 | 25,704.02 | 113.25 | 0.44% |
| Dow JONES (US) | 52,475.10 | 97.53 | 0.19% |
| FTSE 100 | 10,694.50 | 7.96 | 0.07% |
| HKSE | 23,157.73 | 62.90 | 0.27% |
| NASDAQ | 26,549.85 | 72.04 | 0.27% |
| Nikkei 225 | 64,131.28 | 177.09 | 0.28% |
| NZX 50 Index | 13,705.58 | 14.25 | 0.10% |
| S&P 500 | 7,743.98 | 21.38 | 0.28% |
| S&P/ASX 200 | 8,881.20 | 33.90 | 0.38% |
| SSE Composite Index | 3,659.95 | 21.52 | -0.58% |